ProCE Banner Activity

Improving Outcomes for Patients With Advanced NSCLC Through the Optimal Integration of HER2-Targeted Antibody–Drug Conjugate Therapy

Slideset

Downloadable slides with a comprehensive review of the optimal utilization of HER2-targeted treatment strategies for patients with advanced NSCLC from a live event.

Released: October 25, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.